Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (147)

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors

    European Journal of Hospital Pharmacy

  3. Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice

    Antibiotics, Vol. 12, Núm. 3

  4. Automatic Discrimination of Species within the Enterobacter cloacae Complex Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and Supervised Algorithms

    Journal of clinical microbiology, Vol. 61, Núm. 4, pp. e0104922

  5. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  6. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  7. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS

    Journal of medical economics, Vol. 26, Núm. 1, pp. 463-472

  8. Dietary Supplementation with a Cocoa–Carob Blend Modulates Gut Microbiota and Prevents Intestinal Oxidative Stress and Barrier Dysfunction in Zucker Diabetic Rats

    Antioxidants, Vol. 12, Núm. 8

  9. Evaluation of Anti-Neuroinflammatory Activity of Isatin Derivatives in Activated Microglia

    Molecules, Vol. 28, Núm. 12

  10. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 6, pp. 360-370

  11. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  12. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  13. Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

    Journal of Personalized Medicine, Vol. 13, Núm. 3

  14. Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging Assessments in a Mouse Model of Implant-Related Bone and Joint Staphylococcus aureus Infection

    Microbiology spectrum, Vol. 11, Núm. 3, pp. e0454022

  15. Possible heart failure caused by osimertinib in a lung cancer patient

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 1015-1020

  16. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection

    Open Forum Infectious Diseases, Vol. 10, Núm. 2

  17. Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study

    Pharmacological Reports, Vol. 75, Núm. 5, pp. 1254-1264

  18. Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

    Pharmacological Research, Vol. 189